Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally advanced rectal cancers: A phase I-II trial

Cancer Journal

Volumn 11, Issue 2, 2005, Pages 133-139

  Allal, Abdelkarim S ^a   Bieri, Sabine ^b   Gervaz, Pascal ^a   Soravia, Claudio ^a   Bernier, Jacques ^c   Gertsch, Philippe ^c   Morel, Philippe ^a   Roth, Arnaud D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital de Sion   (Switzerland)

^c Regional Hospital San Giovanni   (Switzerland)

Author keywords

Gemcitabine; Radiotherapy; Rectal cancers

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; DEOXYCYTIDINE; DRUG DERIVATIVE; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE; RECTUM CANCER; RECTUM CARCINOMA; RECTUM ULCER; SKIN MANIFESTATION; SKIN TOXICITY; TENESMUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VOMITING; ADJUVANT THERAPY; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; RADIATION DOSE FRACTIONATION; RECTUM TUMOR; SURVIVAL; TIME;

ADULT; AGED; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 23944509117     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200503000-00008     Document Type: Article

References (25)

1. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-987.
2. Camma C, Giunta M, Fiorica F et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000;284: 1008-1015.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
4. Janjan NA, Crane CN, Feig BW et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2000;47:713-718.
5. Allal AS, Bieri S, Bründler M-A et al. Pre-operative hyperfractionated radiotherapy for locally advanced rectal cancers: a phase I-II trial. Int J Radiat Oncol Biol Phys 2002;54:1076-1081.
6. Rich TA, Skibber JM, Ajani JA et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-1029.
7. Ngan SY, Burmeister BH, Fisher R et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2001;50:883-887.
8. Milas L, Fuji T, Hunter N et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-114.
9. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 1996;23:65-71.
10. Lawrence TS, Davis MA, Hough A et al. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001;7:314-319.
11. Pauwels B, Korst AE, Pattyn GG et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075-1083.
12. Wachters FM, van Putten JW, Maring JG et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-562.
13. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24.
14. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
15. Eisbruch A, Shewach DS, Bradford CR et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-799.
16. McGinn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 2003;56:10-15.
17. Blackstock AW, Bernard SA, Richards F et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212.
18. Mohiuddin M, Kudrimoti M, Regine WF et al. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study. Cancer J 2002;8:255-262.
19. Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 2003;14:1285-1290.
20. Boven E, Schippe H, Erkelens CA et al. The influence of schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
21. Blackstock AW, Lightfoot H, Case LD et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001;7:3263-3268.
22. Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-3104.
23. Gerard JP, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003;21:1119-1124.
24. Dunst J, Reese T, Hoelscher T et al. Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer [abstract 1113]. Proc Am Soc Clin Oncol 2003;22:277.
25. Kim JS, Kim JS, Cho MJ et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-408.